Recursion Pharmaceuticals (NASDAQ:RXRX) Director Blake Borgeson Sells 40,000 Shares

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 40,000 shares of the stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $3.96, for a total value of $158,400.00. Following the completion of the sale, the director directly owned 6,218,287 shares of the company’s stock, valued at $24,624,416.52. The trade was a 0.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, June 2nd, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $3.68, for a total value of $110,400.00.
• On Tuesday, May 5th, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $3.52, for a total transaction of $105,600.00.

Recursion Pharmaceuticals Stock Performance

NASDAQ RXRX opened at $3.76 on Friday. Recursion Pharmaceuticals, Inc. has a 1 year low of $2.77 and a 1 year high of $7.18. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.47 and a quick ratio of 5.47. The firm has a market cap of $1.99 billion, a price-to-earnings ratio of -3.13 and a beta of 1.00. The company has a fifty day moving average price of $3.34 and a 200-day moving average price of $3.64.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative net margin of 842.95% and a negative return on equity of 54.33%. The company had revenue of $6.47 million for the quarter, compared to analyst estimates of $15.78 million. During the same period last year, the firm earned ($0.50) earnings per share. The firm’s revenue was down 56.8% on a year-over-year basis. As a group, equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -0.99 EPS for the current fiscal year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. 180 Wealth Advisors LLC raised its holdings in shares of Recursion Pharmaceuticals by 12.3% in the 2nd quarter. 180 Wealth Advisors LLC now owns 190,562 shares of the company’s stock valued at $699,000 after acquiring an additional 20,880 shares in the last quarter. Bank of America Corp DE increased its position in shares of Recursion Pharmaceuticals by 18.2% in the first quarter. Bank of America Corp DE now owns 2,496,831 shares of the company’s stock worth $7,665,000 after purchasing an additional 384,486 shares during the last quarter. Janus Henderson Group PLC increased its position in shares of Recursion Pharmaceuticals by 59.4% in the first quarter. Janus Henderson Group PLC now owns 220,309 shares of the company’s stock worth $675,000 after purchasing an additional 82,100 shares during the last quarter. California State Teachers Retirement System raised its stake in Recursion Pharmaceuticals by 64.0% in the first quarter. California State Teachers Retirement System now owns 574,637 shares of the company’s stock valued at $1,764,000 after purchasing an additional 224,332 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in Recursion Pharmaceuticals by 7.3% in the first quarter. The Manufacturers Life Insurance Company now owns 219,998 shares of the company’s stock valued at $675,000 after purchasing an additional 15,049 shares in the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have weighed in on RXRX shares. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday, May 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 21st. Morgan Stanley raised their price objective on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the company an “equal weight” rating in a research report on Thursday, May 14th. JPMorgan Chase & Co. reduced their price objective on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating for the company in a research note on Thursday, April 30th. Finally, Wall Street Zen lowered shares of Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $8.10.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.